Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 7/20 | 0.59 |
| ▸ | IDH2 | P48735 | 3/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 6/20 | 0.47 |
| ▸ | TEK | Q02763 | 4/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334638 | 0.91 | ALDH1A1 (0.63) | ALDH1A1KDRIDH2BRAFMAPK14 | |
| SCHEMBL4262309 | 0.90 | KDR (0.59) | ALDH1A1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL4255250 | 0.88 | KDR (0.78) | ALDH1A1KDRIDH2BRAFMAPK14 | |
| SCHEMBL14396884 | 0.86 | KDR (0.66) | ALDH1A1KDRIDH2BRAFMAPK14 | |
| SCHEMBL4260334 | 0.85 | KDR (0.78) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL4253258 | 0.84 | KDR (0.62) | KDRIDH2BRAFMAPK14TNNI3K | |
| SCHEMBL4253262 | 0.84 | KDR (0.60) | ALDH1A1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2335476 | 0.83 | RAF1 (0.72) | ALDH1A1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2329806 | 0.82 | KDR (0.62) | ALDH1A1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL4258888 | 0.81 | KDR (0.54) | ALDH1A1KDRIDH2RAF1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | claimed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | claimed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | ALDH1A1 2311/4885KDR 993/4885IDH2 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.